Document:

exv10w15

Exhibit 10.15

Second Services Addendum — Manufacturing Process Support

Date: Dated with effect 11 December 2008

This Second Services Addendum (Second Services Addendum) to the Master Services and Supply
Agreement dated 29 October 2007 between LifeScan, Inc., Universal Biosensors Pty Ltd and Universal
Biosensors, Inc. (Master Agreement) is entered into by and between LifeScan, Inc, a Californian
corporation of 1000 Gibraltar Drive, Milpitas, CA 95035-6312, USA (LifeScan), Universal Biosensors
Pty Ltd ACN 098 234 309, a company incorporated in Victoria, Australia of 1 Corporate Avenue,
Rowville, Victoria 3178, Australia (UBS) and Universal Biosensors, Inc., a Delaware corporation of
having its registered office at c/o Corporation Service Company 2711 Centerville Road, Suite 400,
Wilmington, Delaware 19808 USA (UBI).

The parties agree that this Second Services Addendum is to be attached to, and form part of the
Master Agreement. In relation to the matters addressed in this Second Services Addendum, each of
LifeScan, UBS and UBI agree to be bound by all of the terms and conditions of the Master Agreement
including without limitation Sections 10.3 (Manner of Performing the Services) and 11.4 (Audit
Rights) and each party makes the representations and warranties set forth in the Master Agreement
expressed to be made by LifeScan, UBS or UBI, as the case may be.

All capitalized terms used in this Second Services Addendum and not otherwise defined herein shall
have the meaning ascribed to such terms in the Master Agreement (including all Service Addendums
and Product Addendums).

Background

LifeScan intends to establish its own initial manufacturing line for the Initial Product at a
location of its choosing. As permitted by Section 12(e) of Master Agreement, LifeScan has requested
UBS to assist LifeScan in establishing this manufacturing capacity. The parties desire to set
forth in this Second Services Addendum the services that LifeScan may require from time to time
from UBS, commencing January 1, 2009 and continuing for the Term (as defined in Section 3 below).

1. Manufacturing Support Services to be Provided by UBS

Subject to terms and conditions set forth below and in accordance with the terms of the Master
Agreement, from January 1, 2009 for the Term of this Second Services Addendum, UBS agrees it will
provide the following services (UBS Manufacturing Support Services) to LifeScan with the goal of
assisting LifeScan to establish an initial manufacturing line at a LifeScan facility for the
Initial Product (LifeScan Manufacturing Line):

			
	 	 	 
	Second Services Addendum — Manufacturing Process Support
	 	page 1

 

 

	 	(a)	 	UBS will allow LifeScan’s designated employees (Designated Personnel) access to UBS’s
premises to observe and understand the manufacturing process for the Initial Product
including without limitation to observe UBS’ usual running and maintaining of the equipment
at UBS’ facility and for LifeScan engineers and operators to receive training from UBS.
For purposes of clarification, if any request by LifeScan requires either of the UBS
manufacturing lines to be removed from a validated state, then such activity would not be
included in the UBS Manufacturing Support Services and would be paid for separately by
LifeScan pursuant to a separate purchase order. LifeScan must make a request (which may
include email) to UBS at any time it wishes such access. UBS will provide such access for
Designated Personnel at mutually agreed times which will cause the least disruption to UBS’
commercial operations. LifeScan and UBS will work together to plan access in advance and
agree on mutually convenient times for access to be granted.
	 
	 	(b)	 	UBS will use its best endeavors to cause Harro Höfliger to provide Designated Personnel
with joint access, with UBS, to the factory acceptance testing of UBS’ second suite of
equipment at Harro Höfliger to observe and learn from the equipment testing.
	 
	 	(c)	 	UBS will promptly provide LifeScan and the Designated Personnel copies of any
manufacturing documentation generated by UBS for any UBS manufacturing line for the Initial
Product in the ordinary course of business during the Term. In addition, UBS will promptly
provide LifeScan with a copy of any amendments to such documentation.
	 
	 	(d)	 	UBS will provide LifeScan with access to UBS employees to provide advice to LifeScan to
assist it in establishing its own LifeScan Manufacturing Line. The parties acknowledge that
UBS will initially attempt to provide such advice telephonically or by video conference;
provided, however, that any request for a face to face meeting to provide such advice at a
LifeScan facility would be outside the scope of UBS Manufacturing Support Services. In
addition, UBS will determine which employees are appropriate to provide such advice
(including if considered appropriate by UBS, members of its senior management such as the
Chief Scientist and VP of Operations). Unless otherwise agreed, LifeScan acknowledges that
UBS will be able to give advice based only on its own equipment and experiences and will
not be able to advise LifeScan with respect to aspects of the LifeScan Manufacturing Line
which differ from UBS’ manufacturing line. LifeScan must request these advisory services
from UBS. UBS will provide such advisory services at mutually agreed times which will
cause the least disruption to UBS’ commercial operations. LifeScan and UBS will work
together to plan access in advance and agree on such mutually convenient times for access.
	 
	 	(e)	 	UBS will assist LifeScan with the ordering, installation and validation of such of the
LifeScan Manufacturing Line equipment that is the same as the equipment and configuration
used by UBS. It is acknowledged that UBS may not be able to assist in relation to any
equipment or the

page 2

 

	 	 	 	integration of that equipment into the LifeScan Manufacturing Line which differs from the
equipment and configuration used by UBS.
	 
	 	(f)	 	UBS will cause appropriate employees to cooperate and provide necessary written or
verbal inputs and participate in design reviews and associated meetings with LifeScan to
develop the Functional Design Specification (FDS), User Requirement Specification (URS) and
risk assessments for the LifeScan Manufacturing Line. UBS will cause appropriate employees
to attend relevant LifeScan meetings and present data to assist in the generation of
quality documentation for factory acceptance, site acceptance, installation qualification,
operational qualification and process qualification, stability, regulatory submissions,
equivalence, complaints or Corrective and Preventive Actions (CAPA) for the LifeScan
Manufacturing Line during the Term.

Notwithstanding the above, (i) LifeScan is primarily responsible for organizing and implementing
the establishment of the LifeScan Manufacturing Line. LifeScan is responsible for maintaining
sufficient LifeScan employees to enable it to establish the LifeScan Manufacturing Line for the
Initial Product. LifeScan acknowledges that UBS’capacity to provide the UBS Manufacturing
Support Services may be constrained by UBS’ other commercial activities and that UBS may
postpone the UBS Manufacturing Support Services for a reasonable period if the provision of such
services would:

	 	A.	 	affect UBS’ ability to satisfy its other obligations under the Master Agreement,
including without limitation UBS’ ability to provide other Services or UBS’ ability to
manufacture Product for LifeScan; or
	 
	 	B.	 	materially disrupt or hinder UBS’ other commercial operations; and

(ii) any request by LifeScan for a service that exceeds what is stated above would not be deemed
a UBS Manufacturing Support Service and would be paid for separately by LifeScan pursuant to a
separate purchase order.

2. Consideration for UBS Manufacturing Support Services

In consideration of UBS providing the UBS Manufacturing Support Services, LifeScan agrees:

	 	(a)	 	to pay, an amount of USD2,000,000 on January 31, 2009. For purposes of clarification,
this amount shall only be paid once.
	 
	 	(b)	 	to reimburse UBS for all reasonable out-of pocket, travel and accommodation costs and
expenses incurred with providing the UBS Manufacturing Support Services but with the
understanding the UBS personnel must comply with the written travel policy of LifeScan’s
parent company provided to UBS and LifeScan is only responsible for those expenses incurred
by UBS personnel directly in connection with providing the UBS Manufacturing Support
Services.

All payments shall be paid by LifeScan within 45 days of receipt by LifeScan of an undisputed
invoice in immediately available funds. LifeScan shall promptly notify UBS if it disputes any
portion of any invoice and, subject to the then

page 3

 

current capability of the Accounts Payable system of LifeScan, LifeScan shall pay the undisputed
portion of all such invoices while the dispute is being resolved in accordance with the Master
Agreement.

3. Term.

The UBS Manufacturing Support Services will commence no earlier than January 1, 2009. This Second
Services Addendum shall take effect on the date first written above and shall continue until the
earliest of the following dates: (i) commercial production by LifeScan of 300 million Products at
the LifeScan Manufacturing Line, or (ii) nine months from start of commercial production by the
LifeScan Manufacturing Line or (iii) June 30, 2011.

page 4

 

Executed as an agreement by the duly authorized representative of each Party as of the date first
written above.

	 	 	 	 	 	 	 	 	 
	Executed by LifeScan, Inc.

	 	 	)	 	 	 	 	 
	 

	 	 	)	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Name: John Klopp	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Title: Vice President	 	 
	 
	 	 	 	 	 	 	 	 
	Executed by Universal Biosensors

	 	 	)	 	 	 	 	 
	Pty Ltd

	 	 	)	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	Company Secretary/Director

	 	 	 	 	 	Director	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 

	 	 	 	 	 	 	 	 
	Name of Company Secretary/Director

(print)

	 	 	 	 	 	Name of Director (print)	 	 
	 
	 	 	 	 	 	 	 	 
	Executed by Universal Biosensors,

	 	 	)	 	 	 	 	 
	Inc.

	 	 	)	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Name	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Title	 	 

[Execution Page for Second Services Addendum]

page 5exv10w18xay

Exhibit 10.18(a)

ONCOTHYREON INC.

AMENDMENT TO ROBERT KIRKMAN OFFER LETTER

     This amendment (the “Amendment”) is made by and between Robert Kirkman (“Executive”) and
Oncothyreon Inc. (formerly Biomira Inc.), a Delaware corporation (the “Company” and together with
the Executive hereinafter collectively referred to as the “Parties”) on December 31, 2008.

WITNESSETH:

     WHEREAS, the Parties previously entered into an offer letter, dated August 29, 2006 (the
“Offer Letter”); and

     WHEREAS, the Company and Executive desire to amend certain provisions of the Offer Letter in
order to come into documentary compliance with Section 409A of the Internal Revenue Code of 1986,
as amended (the “Code”), and any final regulations and official guidance promulgated thereunder
(together, “Section 409A”) so as to avoid the imposition of the additional tax imposed under
Section 409A, as set forth below.

     NOW, THEREFORE, for good and valuable consideration, Executive and the Company agree that the
Offer Letter is hereby amended as follows:

1. Severance. Section 5 of the Offer Letter is hereby amended and replaced in its entirety
as follows:

     “5.

     Severance: In the event your employment is terminated for reasons other than
“Cause” (as defined below) or if there is a “Change of Control” as defined in “Exhibit A
of the Option Plan and you remain employed through the date of the Change of Control,
you will be entitled to the following:

     i) Lump sum payment of one year’s base salary, less required withholding,

     ii) Lump sum payment equivalent of variable pay at target for one year following
termination, less required withholding, and,

     iii) Stock options will follow the schedule detailed in item 4.

     Such payments will be made within sixty (60) days following your termination of
employment or the consummation of the Change of Control, as applicable.

     “Cause” for the purpose of this agreement shall include but not be limited to (i)
willful engaging in illegal conduct or gross misconduct which is injurious to the
Company or an affiliated company, (ii) being convicted of, or entering a plea of nolo
contendere or guilty to, a felony or a crime of moral turpitude; (iii) engaging in
fraud,

 

 

misappropriation, embezzlement or any other act or acts of dishonesty resulting or
intended to result directly or indirectly in a gain or personal enrichment to you at the
expense of the Company or an affiliated company, (iv) material breach of any written
policies of the Company or an affiliated company, or (v) willful and continual failure
substantially to perform your duties with the Company, which failure has continued for a
period of at least 30 days after written notice by the Company.

     Section 409A.

          i) Notwithstanding anything to the contrary in this letter agreement, no severance
payable to you, if any, pursuant to this letter agreement that, when considered together
with any other severance payments or separation benefits, are considered deferred
compensation under Section 409A (together, the “Deferred Payments”) will be payable
until you have a “separation from service” within the meaning of Section 409A.
Similarly, no severance payable to you, if any, pursuant to this letter agreement that
otherwise would be exempt from Section 409A pursuant to Treasury Regulation Section
1.409A-1(b)(9) will be payable until you have a “separation from service” within the
meaning of Section 409A.

          ii) Notwithstanding anything to the contrary in this letter agreement, if you are a
“specified employee” within the meaning of Section 409A at the time of your separation
from service, then, if required, the Deferred Payments, which are otherwise due to you
on or within the six (6) month period following your separation from service will
accrue, to the extent required, during such six (6) month period and will become payable
in a lump sum payment on the date six (6) months and one (1) day following the date of
your separation from service or the date of your death, if earlier. All subsequent
Deferred Payments, if any, will be payable in accordance with the payment schedule
applicable to each payment or benefit. Each payment and benefit payable under this
letter agreement is intended to constitute a separate payment for purposes of Treasury
Regulation Section 1.409A-2(b)(2).

          iii) Any amount paid under the letter agreement that satisfies the requirements of
the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury
Regulations will not constitute Deferred Payments for purposes of clause (i) above.

          iv) Any amount paid under this letter agreement that qualifies as a payment made as
a result of an involuntary separation from service pursuant to Section
1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A
Limit will not constitute Deferred Payments for purposes of clause (i) above. “Section
409A Limit” will mean the lesser of two (2) times: (i) your annualized compensation
based upon the annual rate of pay paid to you during your taxable year preceding your
taxable year of your termination of employment as determined under Treasury Regulation
Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with
respect thereto; or (ii) the maximum amount that may be taken into account under a
qualified plan pursuant to Section 401(a)(17) of the Internal Revenue Code for the year
in which your employment is terminated.

-2-

 

          v) The foregoing provisions are intended to comply with the requirements of Section
409A so that none of the severance payments and benefits to be provided hereunder will
be subject to the additional tax imposed under Section 409A, and any ambiguities herein
will be interpreted to so comply. You and the Company agree to work together in good
faith to consider amendments to this letter agreement and to take such reasonable
actions which are necessary, appropriate or desirable to avoid imposition of any
additional tax or income recognition prior to actual payment to you under Section 409A.”

2. Temporary Accommodations. Section 6 of the Offer Letter is hereby amended to add the
following sentence to the end thereof:

“Such temporary accommodations and travel costs provided by the Company is subject to
your continued employment with the Company through each Company provided payment date.”

3. Full Force and Effect. To the extent not expressly amended hereby, the Offer Letter
shall remain in full force and effect.

4. Entire Agreement. This Amendment and the Offer Letter constitute the full and entire
understanding and agreement between the Parties with regard to the subjects hereof and thereof.
This Amendment may be amended at any time only by mutual written agreement of the Parties.

5. Counterparts. This Amendment may be executed in counterparts, all of which together
shall constitute one instrument, and each of which may be executed by less than all of the parties
to this Amendment.

6. Governing Law. This Amendment will be governed by the laws of the State of Washington
(with the exception of its conflict of laws provisions).

-3-

 

     IN WITNESS WHEREOF, each of the Parties has executed this Amendment, in the case of the
Company by its duly authorized officer, as of the date set forth above.

	 	 	 	 	 
	COMPANY	ONCOTHYREON INC.

/s/ Gary Christianson	 
	 
	 	By:  	Gary Christianson	 
	 	Title: 	Chief Operating Officer	 
	 
	EXECUTIVE	 ROBERT KIRKMAN, M.D. 	 
	 	/s/ Robert L. Kirkman, M.D.	 
	 	 	 
	 	 	 
	 

-4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]